Phosphodiesterase 3 Inhibitors
"Phosphodiesterase 3 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 3.
| Descriptor ID |
D058987
|
| MeSH Number(s) |
D27.505.519.389.735.249
|
| Concept/Terms |
Phosphodiesterase 3 Inhibitors- Phosphodiesterase 3 Inhibitors
- Inhibitors, Phosphodiesterase 3
- Phosphodiesterase Type 3 Inhibitors
- PDE-3 Inhibitors
- Inhibitors, PDE-3
- PDE 3 Inhibitors
- PDE3 Inhibitors
- Inhibitors, PDE3
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 3 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 3 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 3 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 3 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase 3 Inhibitors" by people in Profiles.
-
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020 Feb 10; 21(1):47.
-
PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther. 2014 Oct; 28(5):447-57.
-
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
-
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
-
Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther. 2011 Jun; 25(3):223-32.